Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Auxilium Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Entrepreneurs seeking to fund product-focused businesses during the height of the biotech financing boom faced an uphill battle. "Everybody wanted to invest in rocket science in the middle of 2000," notes Gerri Henwood, president, CEO, and founder of Auxilium Pharmaceuticals Inc. Many VCs questioned Auxilium's mission to develop enhanced products for male hormone replacement therapy (HRT). Despite this initial resistance, Henwood persevered, and her comparatively low-risk company garnered increasing VC attention as it breezed through clinical trials on its first product.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel